Medico-legal work 

Medico-legal reports and NHS complaint reviews

Preparation of medico-legal reports and NHS complaint reviews in areas of professional interest, between 100+ completed per year.

Defence                      70%

Complainant                15%

Joint instruction           15%

Dr Falk was retained by the Government’s Department of Energy & Climate Change (now the Department for Business, Energy & Industrial Strategy) in the 'Phurnacite' case regarding a coke plant in South Wales in 2012. In her judgement, The Honourable Mrs Swift noted:
 

'Dr Falk is a Consultant Clinical Oncologist at the Bristol Oncology Centre whose areas of interest include lung cancer and skin cancer. He impressed me as a fair and balanced witness with an excellent knowledge of the relevant epidemiology.

Regarding skin cancer he demonstrated an excellent knowledge of the up-to-date epidemiological literature on the topic and made an impressive witness'.

Recent publications

Falk S Positron Emission Tornography Scanning in Oesophageal Cancer – Stuck at the First Hurdle? Clin Oncol (R Coll Radiol0. 2011 Aug 22. [Epub ahead of print] Hatton M, Nankivell M, Lyn E, Falk S, Pugh C, Navani N, Stephens R, Parmar M.

Induction Chemotherapy and Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for patients with locally advanced inoperable non small cell lung cancer: The MRC INCH Randomised Trial. Int J Radiat Oncol Biol Phys. 2011 Nov 1:81(3). Epub 2010 Oct 6.

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2018 Apr;19(4):562-578

I

Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, Grabsch HI, Langer R, Pritchard S, Okines A, Krysztopik R, Coxon F, Thompson J, Falk S, Robb C, Stenning S, Langley RE. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1249-1260